We show that therapeutic targeting of MCJ in the liver with nanoparticle- and GalNAc-formulated siRNA efficiently reduces liver lipid accumulation and fibrosis in multiple NASH mouse models. Here, DNAJC15 is linked to metabolic dysfunction-associated steatohepatitis.